(101) observed that the antithrombotic drug polydatin blocked the AKT/STAT3/FOXO1 signaling pathway in HCC cells, which increased the levels of phosphorylated AKT, phosphorylated Janus kinase 1, and STAT3, thereby blocking FOXO1. Here, AKT1 is linked to hepatocellular carcinoma.